Wen Shi

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma

David Andorsky, Kathryn S. Kolibaba, Sarit Assouline et al. · British Journal of Haematology · 2018 · 47 citations · Full text

Medicine, Hematology, Oncology +17

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma

John M. Burke, Andrei R. Shustov, James Essell et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 42 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Mechanisms of oral absorption improvement for insoluble drugs by the combination of phospholipid complex and SNEDDS

Yingpeng Tong, Qin Zhang, Wen Shi et al. · Drug Delivery · 2019 · 23 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +17

<p>Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients</p>

Wen Shi, Juan Wu, Qi Tan et al. · Infection and Drug Resistance · 2019 · 22 citations · Full text

Medicine, Pharmacology, Clinical Biochemistry +14

Safety and Efficacy of Oral Nonsteroidal Anti-Inflammatory Drugs in Patients with Rheumatoid Arthritis

Wen Shi, Yong Ming Wang, Li Shao Li et al. · Clinical Drug Investigation · 2004 · 20 citations

Medicine, Pharmacology, Pharmacotherapy +14